SOST and chronic kidney disease: Three out of four assays also confirmed the previously reported positive correlation between plasma FGF23 levels and serum sclerostin levels in CKD patients [29,33], which as evidenced from experimental studies is due to the fact that sclerostin inhibits the protein-encoding gene PHEX [34].